Bluejay Diagnostics Inc
NASDAQ:BJDX
Bluejay Diagnostics Inc
Bluejay Diagnostics, Inc. operates as a diagnostic company. The company is headquartered in Acton, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2021-11-10. The firm is engaged in the developing and marketing minimally invasive point of care (POC) diagnostics tests and devices that provide patients and providers with access to healthcare. The firm offers diagnostic testing in infectious, inflammatory and metabolic diseases by using its Symphony platform. The company focuses on offering solution to the infectious disease, inflammation, and oncology markets. The Company’s ALLEREYE diagnostic test (ALLEREYE) is a POC device that offers healthcare providers a solution for diagnosis of allergic conjunctivitis. The firm's product candidate includes Symphony IL-6 Sepis triage, Symphony IL-6 LDT market, Symphony IL-6 SEPSIS, Symphony hsTNT/I and NT-proBNP. The company is utilizing the platform for detection of sepsis, cancer and other diseases. The company is also developing biomarkers for detection of other diseases, such as cardiac ischemia and congestive heart failure.
Bluejay Diagnostics, Inc. operates as a diagnostic company. The company is headquartered in Acton, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2021-11-10. The firm is engaged in the developing and marketing minimally invasive point of care (POC) diagnostics tests and devices that provide patients and providers with access to healthcare. The firm offers diagnostic testing in infectious, inflammatory and metabolic diseases by using its Symphony platform. The company focuses on offering solution to the infectious disease, inflammation, and oncology markets. The Company’s ALLEREYE diagnostic test (ALLEREYE) is a POC device that offers healthcare providers a solution for diagnosis of allergic conjunctivitis. The firm's product candidate includes Symphony IL-6 Sepis triage, Symphony IL-6 LDT market, Symphony IL-6 SEPSIS, Symphony hsTNT/I and NT-proBNP. The company is utilizing the platform for detection of sepsis, cancer and other diseases. The company is also developing biomarkers for detection of other diseases, such as cardiac ischemia and congestive heart failure.
